ERBB2 and breast cancer: In this study, 1846 patients with node-positive HR+/HER2+ BC achieved similar three-year IDFS rates with three to four cycles of anthracycline-based chemotherapy, followed by 18 cycles of T-DM1 plus pertuzumab (95.4%) or anthracycline-based chemotherapy, followed by taxane plus concurrent trastuzumab plus pertuzumab (94.1%) [106].